Alpine Immune Sciences, Inc. (ALPN)

Market Cap	285.59M
Revenue (ttm)	31.82M
Net Income (ttm)	-54.07M
Shares Out	31.57M
EPS (ttm)	-1.75
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	65,560
Open	6.24
Previous Close	6.22
Day's Range	6 - 6.35
52-Week Range	4.82 - 14.4
Beta	1.38
Analysts	Buy
Price Target	14.03 (+132.3%)
Earnings Date	Nov 14, 2022

About ALPN

Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B...

• Industry: Biotechnology
• CEO: Mitchell Gold
• Employees: 85
• Stock Exchange: NASDAQ
• Ticker Symbol: ALPN

Financial Performance

In 2021, ALPN's revenue was $23.44 million, an increase of 151.13% compared to the previous year's $9.34 million. Losses were -$50.33 million, 80.1% more than in 2020.

Analyst Forecast

According to 11 analysts, the average rating for ALPN stock is "Buy." The 12-month stock price forecast is 14.03, which is an increase of 132.28% from the latest price.

Price Target

$14.03

(132.28% upside)

Analyst Consensus: Buy